Table 1.
Summary of studies included in the meta-analysis
| VPA-treated group |
Healthy controls |
|||||||
|---|---|---|---|---|---|---|---|---|
| Study | Year | Ethnicity | Dose | Duration | Cases | Hcy (μmol/L) | Cases | Hcy (μmol/L) |
| Verrotti et al1 | 2000 | European | 21.7±6.8 mg/kg | 12 months | 32 | 12.7±7.1 | 63 | 7.9±4.5 |
| Karabiber et al2 | 2002 | West Asian | no | >12 months | 30 | 14±6.8 | 29 | 9.2±2.7 |
| Sener et al3 | 2006 | West Asian | no | 6.5±6.2 years | 22 | 17±8.0 | 11 | 11.5±11.4 |
| Vurucu et al7 | 2007 | West Asian | no | 27.36±21.12 months | 64 | 6.88±2.24 | 62 | 5.52±2.53 |
| Kurul et al12 | 2007 | West Asian | no | 4.78±2.07 years | 8 | 7.18±2.54 | 10 | 7.66±2.34 |
| Yildiz et al10 | 2010 | West Asian | 54.49 mg/mL | >6 months | 19 | 6.73±2.81 | 23 | 6.79±1.95 |
| Belcastro et al11 | 2010 | European | 946.4±172 mg/day | >6 months | 37 | 10.4±3.04 | 231 | 9.1±3.04 |
| Chuang et al4 | 2012 | East Asian | 750–1000 mg/day | 8.7±5.2 years | 54 | 13.84±4.29 | 60 | 9.41±2.65 |